Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of Intravenous BNZ-1 in Patients With Moderate to Severe Alopecia Areata
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 19 Sep 2022
Price :
$35
*
At a glance
- Drugs EQ 101 (Primary)
- Indications Alopecia areata
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Bioniz; Equillium
- 14 Sep 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 01 Mar 2022 According to a Equillium media release, enrollment is expected to begin in the second half of 2022.
- 07 Jul 2021 Planned End Date changed from 1 Mar 2021 to 1 Nov 2022.